Mirus Bio Enters into Agreement with Pfizer to Evaluate RNAi Delivery Technology
News Jan 10, 2007
Mirus Bio Corporation has announced it has entered into a two year, multimillion dollar agreement with Pfizer, Inc. to investigate and optimize gene silencing methods in animal models. The studies will utilize Mirus Bio's nucleic acid delivery platforms to target and suppress the expression of genes of interest to Pfizer.
"The lack of effective delivery methods has been the Achilles' heel impeding progress in the emerging field of RNA interference," commented Russell Smestad, Mirus Bio's President.
"We are excited that this agreement will enable us to accelerate the development of our platform technologies. This agreement further enhances our position as one of the industry leaders in providing enabling nucleic acid delivery solutions."
Mirus Bio has two distinct delivery platforms. The first is hydrodynamic intravascular injection, a method designed to deliver nucleic acids through the bloodstream to surrounding cells and tissues.
The second delivery platform involves formulating small interfering RNA (siRNA) into nanoparticles. Unlike the hydrodynamic platform, these nanoparticles are delivered systemically via standard intravenous injection.